RESUMEN
BACKGROUND: Hepatitis C virus (HCV) is a major health issue worldwide. New generation of direct-active antiviral medications is an epoch-making turning point in the management of HCV infections. OBJECTIVE: Conducing a cost-effectiveness analysis comparing the combination of elbasvir/grazoprevir and sofosbuvir + pegylated interferon/ribavirin for the management of all HCV patients (even those in the initial stages of fibrosis). METHODS: A Markov model was built on the natural history of the disease to assess the efficacy of the alternatives. The outcomes are expressed in terms of quality adjusted life-years (QALYs) and result in terms of incremental cost-effectiveness ratio). RESULTS: Elbasvir/grazoprevir implies an expenditure of 21,104,253.74 with a gain of 19,287.90 QALYs and sofosbuvir + pegylated interferon/ribavirin implies an expenditure of 31,904,410.11 with a gain of 18,855.96 QALYs. Elbasvir/grazoprevir is thus a dominant strategy. CONCLUSION: Consideration should be given to the opportunity cost of not treating patients with a lower degree of fibrosis (F0-F2).
Asunto(s)
Antivirales/economía , Benzofuranos/economía , Hepatitis C/economía , Imidazoles/economía , Interferones/economía , Quinoxalinas/economía , Ribavirina/economía , Sofosbuvir/economía , Benzofuranos/uso terapéutico , Costo de Enfermedad , Análisis Costo-Beneficio , Combinación de Medicamentos , Hepacivirus , Hepatitis C/tratamiento farmacológico , Humanos , Imidazoles/uso terapéutico , Interferones/uso terapéutico , Italia , Cadenas de Markov , Años de Vida Ajustados por Calidad de Vida , Quinoxalinas/uso terapéutico , Ribavirina/uso terapéutico , Sofosbuvir/uso terapéuticoRESUMEN
Iron deficiency anaemia (IDA) is the main extraintestinal manifestation affecting patients with inflammatory bowel disease (IBD). The Health Technology Assessment approach was applied to evaluate the sustainability of intravenous (IV) iron formulations in the Italian hospital setting, with particular focus on ferric carboxymaltose. Data on the epidemiology of IBD and associated IDA, in addition to the efficacy and safety of IV iron formulations currently used in Italy, were retrieved from scientific literature. A hospital-based cost-analysis of the outpatient delivery of IV iron treatments was performed. Organizational and ethical implications were discussed. IDA prevalence in IBD patients varies markedly from 9 to 73%. IV iron preparations were proven to have good efficacy and safety profiles, and ferric carboxymaltose provided a fast correction of haemoglobin and serum ferritin levels in iron-deficient patients. Despite a higher price, ferric carboxymaltose would confer a beneficial effect to the hospital, in terms of reduced cost related to individual patient management and additionally to the patient by reducing the number of infusions and admissions to healthcare facilities. Ethically, the evaluation is appropriate due to its efficacy and compliance. This assessment supports the introduction of ferric carboxymaltose in the Italian outpatient setting.
Asunto(s)
Anemia Ferropénica/tratamiento farmacológico , Anemia Ferropénica/etiología , Enfermedades Inflamatorias del Intestino/complicaciones , Hierro/administración & dosificación , Administración Intravenosa/métodos , Anemia Ferropénica/metabolismo , Compuestos Férricos/metabolismo , Hemoglobinas/metabolismo , Hospitales , Humanos , Enfermedades Inflamatorias del Intestino/metabolismo , Infusiones Intravenosas/métodos , Italia , Maltosa/análogos & derivados , Maltosa/metabolismo , Evaluación de la Tecnología Biomédica/métodos , Resultado del TratamientoRESUMEN
OBJECTIVE: To evaluate the quality of life among doctors, nurses, and occupational safety and health technologists (OSHT). STUDY DESIGN: Cross-sectional study was undertaken in a population of healthcare workers in 10 Italian regions. METHODS: The Italian version of short form-36 (SF-36) was anonymously and voluntarily self-administered by participants to assess the perceived health-related quality of life (HRQOL). The HRQOL scores for the sample and the Italian population were compared. A multiple linear regression was performed to assess the influence of age, gender, role, socializing time, working time, years spent in healthcare and years spent in the specific department on the SF-36 score. RESULTS: The sample included 324 healthcare workers [57.1% women, mean age 39.0 (standard deviation 10.2) years]: 52.6% were medical doctors, 36.8% were nurses and 10.5% were OSHTs. Workers with a career of >15 years achieved a general health score lower than that of workers with a shorter career, while those who spent more time in socializing activities achieved a higher mental health score. The multivariate analysis showed that increasing age is positively related to role emotional levels (ß = 0.243; P = 0.002), while it appears to be inversely related to general health (ß = -0.218; P = 0.007) and physical function (ß = -0.246; P = 0.001). Nurses had lower scores for bodily pain (ß = -0.214; P < 0.001), social function (ß = -0.242; P = 0.001) and role emotional (ß = -0.211; P = 0.006) compared with doctors. Compared with the general Italian population, healthcare workers had higher scores for general health, physical function, role physical, bodily pain and mental health, and lower scores for vitality, social function and role emotional. CONCLUSIONS: Healthcare workers have different levels of HRQOL related to their professional role. In particular, nurses have lower quality of life. These results may help to identify the main roles and attitudes that could cause frustration, dissatisfaction and emotional stress in healthcare workers.